DOI:
10.1039/D5OB01000D
(Communication)
Org. Biomol. Chem., 2025,
23, 7935-7939
Synthesis of axially chiral 5,5′-substituted 2,2′-bipyridine ligands and their application in palladium-catalyzed asymmetric oxidative [2 + 2] annulation
Received
19th June 2025
, Accepted 11th August 2025
First published on 12th August 2025
Abstract
A series of axially chiral 5,5′-substituted 2,2′-bipyridine ligands featuring tunable properties have been synthesized. These ligands have been successfully applied to palladium-catalyzed asymmetric oxidative [2 + 2] annulation of arylboronic acids and alkenes, providing a diverse range of chiral benzocyclobutenes in excellent enantioselectivities with a broad substrate scope.
In modern synthetic chemistry, the innovation of novel chiral ligands has been a crucial area of asymmetric catalysis.1 Owing to their robust stability and easy functionalization, chiral N,N-ligands have occupied a predominant position in enantioselective synthesis.1a,2 Among the various types of chiral N,N-ligands, chiral 2,2′-bipyridine ligands have served as some of the notable representatives. Since the first development of chiral monoalkyl-substituted 2,2′-bipyridine ligands by Botteghi's group in 1984,3 a diverse series of chiral 2,2′-bipyridine ligands have been designed and extensively applied in the last four decades.4–6 These privileged chiral ligands consist of centrally-chiral bipyridine ligands,4 planarly-chiral bipyridine ligands,5 and axially-chiral bipyridine ligands.6 In 2015, our group developed axially chiral 2,2′-bipyridine ligands (abbreviated as Cn-ACBP) through the remote chirality delivery strategy (Scheme 1a).6a These axially chiral ligands have been successfully utilized in versatile transition metal-catalyzed asymmetric reactions, including palladium-catalyzed enantioselective C–H functionalization of indoles6a and pyrroles,6b O–H insertion reaction of phenols,6a intramolecular C(sp3)–H insertion of donor–donor carbenes,6c arylation of N-tosylaryl-imines,6d cyclization of aniline-tethered alkynyl cyclohexadienones,6e and so on.6f–i Although our axially chiral 2,2′-bipyridine ligands have displayed superior performance in asymmetric catalysis, the exploration of more tunable and applicable axially chiral 2,2′-bipyridine ligands is still in demand. Conventionally, the introduction of substituents to the 6,6′-positions of 2,2′-bipyridine ligands would cause remarkable steric hindrance to the transition metal center and reduce the reactivity. In order to overcome this obstacle, we envisioned developing axially chiral 5,5′-substituted 2,2′-bipyridine ligands (abbreviated as 5,5′-R2-Cn-ACBP), which would fine-tune the electronic properties by regulating different substituents and exhibit slight steric hindrance effects simultaneously to ensure high reactivity and stereoselectivity (Scheme 1a).
 |
| | Scheme 1 Axially chiral 5,5′-substituted 2,2′-bipyridine ligands enabled palladium-catalyzed asymmetric oxidative [2 + 2] annulation. | |
Benzocyclobutenes have emerged as vital structural motifs in natural products and bioactive molecules.7 Due to the significant importance of benzocyclobutenes, considerable attention has been paid to them and various synthetic methods have been developed.8,9 Recently, palladium-catalyzed oxidative [2 + 2] annulation has been a useful and straightforward protocol to construct benzocyclobutenes.10 In 2022, Zhu and coworkers disclosed an elegant synthesis of functionalized benzocyclobutenes via palladium-catalyzed oxidative [2 + 2] annulation of arylboronic acids with alkenes using an achiral 2,2′-bipyridine as a ligand.11 They also reported a single catalytic asymmetric version of this reaction, delivering the target chiral benzocyclobutene product with 58% ee in the presence of a chiral pyridine–imine ligand. Last year, Yang's group realized a Pd/Pyrox-catalyzed asymmetric oxidative [2 + 2] annulation to afford a wide range of chiral benzocyclobutenes (Scheme 1b).12 Based on the exceptional catalytic efficacy of chiral N,N-ligands in this reaction and the advantages of axially chiral 5,5′-substituted 2,2′-bipyridine ligands, we envisaged applying 5,5′-R2-Cn-ACBP ligands in palladium-catalyzed asymmetric annulation to ensure both reactivity and enantioselectivity. Herein, we reported the synthesis of axially chiral 5,5′-substituted 2,2′-bipyridine ligands and their application in palladium-catalyzed asymmetric oxidative annulation of arylboronic acids with alkenes for the synthesis of benzocyclobutenes with excellent enantioselectivities (Scheme 1b).
Axially chiral 5,5′-substituted 2,2′-bipyridine ligands were synthesized through the approach shown in Scheme 2. A wide range of 5,5′-R2-Cn-ACBP ligands were conveniently synthesized through two steps from easily available chiral (2R,5R)-hexane-2,5-diyl dimethanesulfonate and variable 5-substituted 2-iodo-3-hydroxypyridines S1 which can be obtained from 3-hydroxy-5-bromopyridine or 3-(benzyloxy)-5-bromopyridine via cross-coupling and iodination. Initiated by the SN2 reaction and followed by Ullmann coupling, various 5,5′-R2-Cn-ACBP ligands L1–L10 bearing diverse alkyl and aryl substituents at 5,5′-positions were obtained in moderate 28–60% yields.
 |
| | Scheme 2 Synthesis of axially chiral 5,5′-substituted 2,2′-bipyridine ligands. | |
With the axially chiral 2,2′-bipyridine ligands in hand, we began our investigation on palladium-catalyzed asymmetric oxidative [2 + 2] annulations. Initially, 2,2-dimethyl-1-morpho-linobut-3-en-1-one 1a and phenylboronic acid 2a were chosen as the model substrates to perform the reaction at 40 °C using (Ra,S,S)-3,3′-(1,4-dimethylbutanedioxy)-2,2′-bipyridine (abbreviated as C4-ACBP) as a ligand and benzotrifluoride as solvent. Satisfyingly, the target product 3aa was obtained in 38% yield with 82% ee (Table 1, entry 1). Further evaluation of solvents revealed that tetrahydrofuran (THF) afforded comparable results to benzotrifluoride (entry 2). 1,2-Dichloroethane (DCE) proved optimal, delivering product 3aa in 40% yield with 95% ee (entry 3).
Table 1 Optimization of reaction conditions
|

|
| Entrya |
Solvent |
L*
|
Yieldb (%) |
eec (%) |
|
Reaction conditions: 1a (0.10 mmol), phenylboronic acid 2a (0.20 mmol), Pd(OAc)2 (10 mol%), L* (12 mol%), NFSI (1.3 equiv.), Ag2O (1.0 equiv.), 5 Å MS (30 mg), solvent (1.0 mL), 40 °C, 22 hours.
The yield was measured by analysis of 1H NMR spectra, using diphenyl acetonitrile as the internal standard.
Determined by chiral HPLC.
AgOTf (20 mol%) was added.
AgSbF6 (30 mol%) was added.
The reaction was conducted on a 0.30 mmol scale; L5 (10 mol%), AgOTf (20 mol%) and AgSbF6 (30 mol%) were added; 3 h.
Isolated yield.
|
| 1 |
PhCF3 |
C4-ACBP
|
38 |
82 |
| 2 |
THF |
C4-ACBP
|
39 |
84 |
| 3 |
DCE |
C4-ACBP
|
40 |
95 |
| 4 |
DCE |
C2-ACBP
|
45 |
53 |
| 5 |
DCE |
C3-ACBP
|
37 |
91 |
| 6 |
DCE |
L1
|
39 |
93 |
| 7 |
DCE |
L2
|
33 |
83 |
| 8 |
DCE |
L3
|
37 |
92 |
| 9 |
DCE |
L4
|
46 |
90 |
| 10 |
DCE |
L5
|
52 |
91 |
| 11 |
DCE |
L6
|
47 |
80 |
| 12 |
DCE |
L7
|
40 |
89 |
| 13 |
DCE |
L8
|
48 |
92 |
| 14 |
DCE |
L9
|
41 |
91 |
| 15 |
DCE |
L10
|
40 |
93 |
| 16d |
DCE |
L5
|
56 |
89 |
| 17e |
DCE |
L5
|
49 |
93 |
| 18f |
DCE |
L5
|
65g |
91 |
Afterwards, (Ra,S,S)-3,3′-(1,2-dimethylethylenedioxy)-2,2′-bipyridine (abbreviated as C2-ACBP) and (Ra,S,S)-3,3′-(1,3-dimethylpropanedioxy)-2,2′-bipyridine (abbreviated as C3-ACBP) ligands were evaluated. Compared with the C4-ACBP ligand, the C2-ACBP ligand diminished enantioselectivity, although slightly increased the yield (entry 4). The C3-ACBP ligand resulted in both diminished yield and enantioselectivity (entry 5). In order to further improve the yield and maintain the enantioselectivity, a number of 5,5′-R2-C4-ACBP ligands bearing diverse substituents were screened. Ligands bearing alkyl groups L1–L3 exhibited inferior results compared to C4-ACBP (entries 6–8). When the phenyl substituted ligand L4 was utilized, the yield could be enhanced to 46% and the ee value was 90% (entry 9). Notably, L5 bearing p-methylphenyl groups was the most efficient ligand, affording the desired product in 52% yield and 91% ee (entry 10). L6–L9 containing aromatic substituents with different electronic properties behaved worse than L5 (entries 11–14). L10 with bulky groups reduced the yield of the reaction (entry 15). Since silver salt additives play a crucial role in palladium-catalyzed C–H activation,13 the investigation of silver salt additives was conducted. It was found that the addition of AgOTf could improve the yield of the reaction but slightly decreased the enantioselectivity (entry 16). The addition of AgSbF6 could improve the enantioselectivity to 93%, but reduced the yield to 49% (entry 17). To achieve a better yield and enantioselectivity at the same time, the combination of AgOTf and AgSbF6 was adopted (see the SI for details). When both AgOTf and AgSbF6 were added and the loading of ligand L5 was reduced to 10 mol%, the enantiomeric excess of 3aa was maintained at 91% with a significant improvement of yield to 65% (entry 18).
Upon establishing the reliable reaction conditions, we explored the substrate scope of this enantioselective [2 + 2] annulation by varying alkenes 1 and arylboronic acids 2 (Scheme 3). First, we investigated the arylboronic acid components. 4-Alkyl substituted arylboronic acids furnished the benzocyclobutenes 3ab–3ae in moderate yields with 87%–92% ee values. 4-Phenyl substituted arylboronic acid 2f was accommodated. Arylboronic acids with electron-withdrawing substituents were appropriate reaction partners. (4-Formylphenyl)boronic acid 2g and (4-acetylphenyl)boronic acid 2h and smoothly underwent the annulation with 94% and 89% ee values. (4-(Methoxycarbonyl)phenyl)boronic acid 2i afforded desirable benzocyclobutene with excellent 93% enantioselectivity. (4-(Trimethylsilyl)phenyl)boronic acid 2j was also tolerated, giving good enantioselectivity and a moderate yield. When arylboronic acids bearing a halogen at the 4-position were used, the corresponding benzocyclobutenes (3ak–3am) were obtained in moderate yields and excellent enantioselectivities using Pd(OPiv)2 and L4 as the catalyst. 3-Substituted (2n, 2o) and 3,5-disubstituted (2p) arylboronic acids were suitable for the asymmetric reaction, affording the desired products 3an–3ap with good enantioselectivities. Moreover, a range of alkenes 1 were examined with phenylboronic acid. The amide moiety in alkene 1 derived from piperidine (1b) and linear amides (1c–1e) were tolerated. Finally, the alkene with a cyclic gem-disubstituted group (1f) could also afford the corresponding benzocyclobutene in a moderate yield with 92% ee.
 |
| | Scheme 3 Substrate scope: alkenes 1 and arylboronic acids 2. | |
To demonstrate the scalability of the strategy, a 1.0 mmol scale experiment was performed to provide the desirable chiral product 3aa in 63% yield with 91% ee, which is consistent with the result of a 0.30 mmol scale (Scheme 4a). Then product 3aa underwent reduction with LiAlH4 to give a chiral amine in 89% yield and 91% ee (Scheme 4b).
 |
| | Scheme 4 Experiment on a 1.0 mmol scale and synthetic transformation. | |
Conclusions
In conclusion, we successfully synthesized a class of axially chiral 5,5′-substituted 2,2′-bipyridine ligands, featuring tunable properties. These ligands would finely regulate the electronic characteristics by introducing different substituents to 5,5′-positions and slightly affect the steric hindrance. These ligands were applied in palladium-catalyzed oxidative [2 + 2] annulation of arylboronic acids and alkenes to afford chiral benzocyclobutenes in excellent enantioselectivities. These results suggested the promising potential of axially chiral ligands as a useful class of chiral N,N-ligands. Further explorations on the application of these ligands in asymmetric catalysis are ongoing in our laboratory.
Author contributions
Kai Xue: methodology, investigation and writing – review & editing. Jian Chen: validation. Yu-Qing Bai: validation. Bo Wu: conceptualization, validation, supervision, and writing – review & editing. Yong-Gui Zhou: conceptualization, validation, supervision, and writing – review & editing.
Conflicts of interest
There are no conflicts to declare.
Data availability
The data supporting this communication have been included as part of the SI: experimental procedures, synthesis of ligands, characterization data, and copies of the 1H, 13C, 19F NMR spectra of all new compounds are included. See DOI: https://doi.org/10.1039/d5ob01000d.
Acknowledgements
Financial support from the National Key Research and Development Program of China (2023YFA1507500), National Natural Science Foundation of China (22171260), Natural Science Foundation of Liaoning Province (2023-MS-009) and Dalian Institute of Chemical Physics (DICP I202404, I202241) is acknowledged.
References
-
(a)
L. M. Stanley and M. P. Sibi, Privileged Chiral Ligands and Catalysts, John Wiley & Sons, Ltd, 2011, pp. 171–219 Search PubMed;
(b) T. P. Yoon and E. N. Jacobsen, Science, 2003, 299, 1691 CrossRef CAS PubMed.
-
(a) F. Fache, E. Schulz, M. L. Tommasino and M. Lemaire, Chem. Rev., 2000, 100, 2159 CrossRef CAS PubMed;
(b) N. C. Fletcher, J. Chem. Soc., Perkin Trans. 1, 2002, 1831 RSC;
(c) H.-L. Kwong, H.-L. Yeung, C.-T. Yeung, W.-S. Lee, C.-S. Lee and W.-L. Wong, Coord. Chem. Rev., 2007, 251, 2188 CrossRef CAS;
(d) G. Yang and W. Zhang, Chem. Soc. Rev., 2018, 47, 1783 RSC;
(e) R. Connon, B. Roche, B. V. Rokade and P. J. Guiry, Chem. Rev., 2021, 121, 6373 CrossRef CAS PubMed.
- C. Botteghi, G. Caccia, G. Chelucci and F. Soccolini, J. Org. Chem., 1984, 49, 4290 CrossRef CAS.
-
(a) G. Chelucci and R. P. Thummel, Chem. Rev., 2002, 102, 3129 CrossRef CAS PubMed;
(b) K. Ito and T. Katsuki, Synlett, 1993, 638 CrossRef CAS;
(c) D. Lötscher, S. Rupprecht, H. Stoeckli-Evans and A. von Zelewsky, Tetrahedron: Asymmetry, 2000, 11, 4341 CrossRef;
(d) A. V. Malkov, M. Bella, V. Langer and P. Kočovský, Org. Lett., 2000, 2, 3047 CrossRef CAS;
(e) A. V. Malkov, D. Pernazza, M. Bell, M. Bella, A. Massa, F. Teplý, P. Meghani and P. Kočovský, J. Org. Chem., 2003, 68, 4727 CrossRef CAS PubMed;
(f) T. Kitanosono, L. Zhu, C. Liu, P. Xu and S. Kobayashi, J. Am. Chem. Soc., 2015, 137, 15422 CrossRef CAS PubMed;
(g) S. Lauzon, H. Keipour, V. Gandon and T. Ollevier, Org. Lett., 2017, 19, 6324 CrossRef CAS;
(h) T. Kitanosono, P. Xu and S. Kobayashi, Science, 2018, 362, 311 CrossRef CAS PubMed;
(i) T. Kitanosono, T. Hisada, Y. Yamashita and S. Kobayashi, Angew. Chem., Int. Ed., 2021, 60, 3407 CrossRef CAS;
(j) S. Lauzon, L. Caron and T. Ollevier, Org. Chem. Front., 2021, 8, 2242 RSC;
(k) P. S. Riehl, A. D. Richardson, T. Sakamoto, J. P. Reid and C. S. Schindler, Chem. Sci., 2021, 12, 14133 RSC;
(l) Y. Ouyang, M. Zhan, J. Zhou, J. Jiao, H. Hu, Y. M. A. Yamada and P. Li, Chin. J. Chem., 2019, 37, 807 CrossRef CAS;
(m) S. Zhang, S. Perveen, Y. Ouyang, L. Xu, T. Yu, M. Zhao, L. Wang, P. Song and P. Li, Angew. Chem., Int. Ed., 2022, 61, e202117843 CrossRef CAS;
(n) S. Perveen, S. Zhang, L. Wang, P. Song, Y. Ouyang, J. Jiao, X.-H. Duan and P. Li, Angew. Chem., Int. Ed., 2022, 61, e202212108 CrossRef CAS PubMed;
(o) L. Wang, T. Li, S. Perveen, S. Zhang, X. Wang, Y. Ouyang and P. Li, Angew. Chem., Int. Ed., 2022, 61, e202213943 CrossRef CAS.
-
(a) R. Rios, J. Liang, M. M.-C. Lo and G. C. Fu, Chem. Commun., 2000, 377 RSC;
(b) G. C. Fu, Acc. Chem. Res., 2006, 39, 853 CrossRef CAS PubMed.
-
(a) X. Gao, B. Wu, W.-X. Huang, M.-W. Chen and Y.-G. Zhou, Angew. Chem., Int. Ed., 2015, 54, 11956 CrossRef CAS PubMed;
(b) H.-Q. Shen, C. Liu, J. Zhou and Y.-G. Zhou, Org. Chem. Front., 2018, 5, 611 RSC;
(c) W. Li, H. Zhang, K. Chen, H. Jiang, J. Sun and S. Zhu, Chem. Sci., 2022, 13, 12396 RSC;
(d) X. Gao, B. Wu, Z. Yan and Y.-G. Zhou, Org. Biomol. Chem., 2016, 14, 55 RSC;
(e) J. Chen, X. Han and X. Lu, Angew. Chem., Int. Ed., 2017, 56, 14698 CrossRef CAS PubMed;
(f) X. Gao, B. Wu, Z. Yan and Y.-G. Zhou, Org. Biomol. Chem., 2016, 14, 8237 RSC;
(g) Q.-Q. Zhou, F.-D. Lu, D. Liu, L.-Q. Lu and W.-J. Xiao, Org. Chem. Front., 2018, 5, 3098 RSC;
(h) K. Dong, T. Wu, M. Wang and L. Lin, Angew. Chem., Int. Ed., 2024, 63, e202411158 CAS;
(i) H. Yang, X. Sun, Z. Chen, C. Jiang, L. Duan, J. Zhao and Z. Gu, Angew. Chem., Int. Ed., 2025, 64, e202416839 CrossRef CAS PubMed.
-
(a) G. Mehta and S. Kotha, Tetrahedron, 2001, 57, 625 CrossRef CAS;
(b) B. Yang and S. Gao, Chem. Soc. Rev., 2018, 47, 7926 RSC;
(c) I. Kouno, T. Komori and T. Kawasaki, Tetrahedron Lett., 1973, 14, 4569 CrossRef;
(d) V. H. Rawal and M. P. Cava, Tetrahedron Lett., 1983, 24, 5581 CrossRef CAS;
(e) R. A. Kirchhoff and K. J. Bruza, Prog. Polym. Sci., 1993, 18, 85 CrossRef CAS;
(f) H.-H. Ko, C.-N. Lin and S.-Z. Yang, Helv. Chim. Acta, 2000, 83, 3000 CrossRef CAS;
(g) M. A. Psotka and J. R. Teerlink, Circulation, 2016, 133, 2066 CrossRef CAS.
-
(a) I. L. Klundt, Chem. Rev., 1970, 70, 471 CrossRef CAS;
(b) A. K. Sadana, R. K. Saini and W. E. Billups, Chem. Rev., 2003, 103, 1539 CrossRef CAS PubMed;
(c) R. Davenport, M. Silvi, A. Noble, Z. Hosni, N. Fey and V. K. Aggarwal, Angew. Chem., Int. Ed., 2020, 59, 6525 CrossRef CAS PubMed.
-
(a) G. Dyker, Angew. Chem., Int. Ed. Engl., 1994, 33, 103 CrossRef;
(b) O. Baudoin, A. Herrbach and F. Guéritte, Angew. Chem., Int. Ed., 2003, 42, 5736 CrossRef CAS PubMed;
(c) M. Chaumontet, R. Piccardi, N. Audic, J. Hitce, J.-L. Peglion, E. Clot and O. Baudoin, J. Am. Chem. Soc., 2008, 130, 15157 CrossRef CAS;
(d) S. Rousseaux, M. Davi, J. Sofack-Kreutzer, C. Pierre, C. E. Kefalidis, E. Clot, K. Fagnou and O. Baudoin, J. Am. Chem. Soc., 2010, 132, 10706 CrossRef CAS PubMed;
(e) C. E. Kefalidis, M. Davi, P. M. Holstein, E. Clot and O. Baudoin, J. Org. Chem., 2014, 79, 11903 CrossRef CAS;
(f) Z. Wu, D. Ma, B. Zhou, X. Ji, X. Ma, X. Wang and Y. Zhang, Angew. Chem., Int. Ed., 2017, 56, 12288 CrossRef CAS PubMed;
(g) J. Ye, Z. Shi, T. Sperger, Y. Yasukawa, C. Kingston, F. Schoenebeck and M. Lautens, Nat. Chem., 2017, 9, 361 CrossRef CAS PubMed;
(h) P. A. Provencher, J. F. Hoskin, J. J. Wong, X. Chen, J.-Q. Yu, K. N. Houk and E. J. Sorensen, J. Am. Chem. Soc., 2021, 143, 20035 CrossRef CAS PubMed;
(i) W.-X. Wei, Y. Li, Y.-T. Wen, M. Li, X.-S. Li, C.-T. Wang, H.-C. Liu, Y. Xia, B.-S. Zhang, R.-Q. Jiao and Y.-M. Liang, J. Am. Chem. Soc., 2021, 143, 7868 CrossRef CAS PubMed.
-
(a) S. Kotha, K. Lahiri and Y. Tangella, Asian J. Org. Chem., 2021, 10, 3166 CrossRef CAS;
(b) M. Catellani, G. P. Chiusoli and S. Ricotti, J. Organomet. Chem., 1985, 296, c11 CrossRef CAS;
(c) M. Catellani and L. Ferioli, Synthesis, 1996, 769 CrossRef CAS;
(d) D. I. Chai, P. Thansandote and M. Lautens, Chem. – Eur. J., 2011, 17, 8175 CrossRef CAS PubMed;
(e) X. Wu and J. Zhou, Chem. Commun., 2013, 49, 11035 RSC;
(f) T. Nanjo, C. Tsukano and Y. Takemoto, Chem. Pharm. Bull., 2016, 64, 1384 CrossRef CAS PubMed;
(g) P. Annamalai, H.-C. Hsiao, S. Raju, Y.-H. Fu, P.-L. Chen, J.-C. Horng, Y.-H. Liu and S.-C. Chuang, Org. Lett., 2019, 21, 1182 CrossRef CAS PubMed;
(h) J.-M. Yang, Y.-K. Lin, T. Sheng, L. Hu, X.-P. Cai and J.-Q. Yu, Science, 2023, 380, 639 CrossRef CAS PubMed.
- T. Fujii, S. Gallarati, C. Corminboeuf, Q. Wang and J. Zhu, J. Am. Chem. Soc., 2022, 144, 8920 CrossRef CAS PubMed.
- P. K. Pramanick, S. Zhao, H.-T. Ji, X. Chen and G. Yang, Angew. Chem., Int. Ed., 2025, 64, e202415927 CrossRef CAS PubMed.
- For Pd–Ag heterobimetallic intermediate species in C–H activation, see:
(a) R. L. de Carvalho, E. B. T. Diogo, S. L. Homölle, S. Dana, E. N. da Silva Júnior and L. Ackermann, Chem. Soc. Rev., 2023, 52, 6359 RSC;
(b) K. L. Bay, Y.-F. Yang and K. N. Houk, J. Organomet. Chem., 2018, 864, 19 CrossRef CAS;
(c) T. Bhattacharya, S. Dutta and D. Maiti, ACS Catal., 2021, 11, 9702 CrossRef CAS;
(d) S. Ghosh, S. Shilpa, C. Athira and R. B. Sunoj, Top. Catal., 2022, 65, 141 CrossRef CAS.
|
| This journal is © The Royal Society of Chemistry 2025 |
Click here to see how this site uses Cookies. View our privacy policy here.